Seres Therapeutics Pauses SER-155 Investment, Cuts Workforce to Extend Cash Runway
Event summary
- Seres Therapeutics has paused further investment in the Phase 2 study of SER-155 for allogeneic hematopoietic stem cell transplant (allo-HSCT) while seeking funding.
- The company reduced its workforce by approximately 30% to extend its cash runway through Q3 2026.
- Seres will focus on advancing early-stage live biotherapeutic programs in inflammatory and immune diseases.
- Initial clinical results from the fully enrolled Investigator-sponsored SER-155 study in immune checkpoint related enterocolitis (irEC) are expected in early Q2 2026.
The big picture
Seres Therapeutics is navigating a strategic pivot by pausing investment in its SER-155 Phase 2 study and focusing on early-stage programs amid cost-reduction measures. This shift reflects broader industry trends where biotech companies balance clinical development with financial sustainability, especially in the competitive landscape of inflammatory and immune diseases. The company's actions highlight the challenges of securing funding for late-stage clinical trials while maintaining momentum in pipeline development.
What we're watching
- Funding Strategy
- Whether Seres can secure additional funding to resume the SER-155 Phase 2 study and support its early-stage pipeline programs.
- Clinical Data
- The impact of the upcoming SER-155 clinical data in irEC on the potential broader use cases for live biotherapeutics.
- Strategic Pivot
- The pace at which Seres can advance its early-stage programs and explore collaborations to provide additional capital.
Related topics